赛诺菲(SNY.US)BTK抑制剂Tolebrutinib有效延缓MS患者残疾进展

智通财经09-20

智通财经APP获悉，赛诺菲(SNY.US)周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症(MS)患者的残疾进展延缓31%。这一数据证实了赛诺菲在9月初发表的研究结果。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。而这是...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2468840643?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-20 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468840643","market":"hk","top_or_hot":-1,"title":"赛诺菲(SNY.US)BTK抑制剂Tolebrutinib有效延缓MS患者残疾进展","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，赛诺菲(SNY.US)周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症(MS)患者的残疾进展延缓31%。这一数据证实了赛诺菲在9月初发表的研究结果。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。而这是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1185309.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛诺菲(SNY.US)BTK抑制剂Tolebrutinib有效延缓MS患者残疾进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛诺菲(SNY.US)BTK抑制剂Tolebrutinib有效延缓MS患者残疾进展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-20 18:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1185309.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，赛诺菲(SNY.US)周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症(MS)患者的残疾进展延缓31%。这一数据证实了赛诺菲在9月初发表的研究结果。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。而这是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1185309.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1185309.html","article_id":"2468840643","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468840643","pubTimestamp":1726827422,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，赛诺菲周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症患者的残疾进展延缓31%。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。赛诺菲计划在今年向全球监管机构提交该药物。不过，试验显示，接受Tolebrutinib治疗的患者不良事件略多，最令人担忧的是肝酶升高。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SNY":"赛诺菲安万特","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4588":"碎股","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0106831901.USD":"贝莱德世界金融基金A2","BK4581":"高盛持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4504":"桥水持仓","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4127":"投资银行业与经纪业","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"translate_title":"Sanofi (SNY.US) BTK inhibitor Tolebrutinib effectively delays the progression of disability in MS patients","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1},"content_text":"智通财经APP获悉，赛诺菲(SNY.US)周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症(MS)患者的残疾进展延缓31%。这一数据证实了赛诺菲在9月初发表的研究结果。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。而这是首个也是唯一一个显示非复发继发性进行性多发性硬化症(MS)残疾积累减少的研究。据悉，非复发继发性进行性多发性硬化症目前尚无获得批准的治疗方法。克利夫兰诊所神经学研究所研究副主席、赛诺菲试验顾问Robert Fox将最新试验的发现描述为“巨大的突破”。赛诺菲计划在今年向全球监管机构提交该药物。Bloomberg Intelligence分析师John Murphy在一份报告中表示，Tolebrutinib的成功可能会给赛诺菲带来17亿美元的潜在收入，在最乐观的情况下可能会带来36亿美元的收入。不过，试验显示，接受Tolebrutinib治疗的患者不良事件略多，最令人担忧的是肝酶升高。赛诺菲在一份声明中表示，在试验实施更严格的监测之前，一名患者不得不接受肝移植，并因术后并发症而死亡。Robert Fox表示，研究人员希望在治疗的前90天内通过密切监测来控制不良事件的发生。他表示，如果该疗法获得批准，患者将需要与临床医生一起权衡该疗法的风险与益处。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468840643"}